Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CFO Sells $17,955.00 in Stock

Posted by Defense World Staff on Mar 6th, 2023

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT – Get Rating) CFO William Garrett Gray sold 3,591 shares of the company’s stock in a transaction that occurred on Thursday, March 2nd. The stock was sold at an average price of $5.00, for a total transaction of $17,955.00. Following the sale, the chief financial officer now directly owns 51,374 shares in the company, valued at approximately $256,870. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

William Garrett Gray also recently made the following trade(s):

On Monday, February 27th, William Garrett Gray sold 1,914 shares of Checkpoint Therapeutics stock. The stock was sold at an average price of $4.66, for a total transaction of $8,919.24.
On Wednesday, February 1st, William Garrett Gray sold 3,154 shares of Checkpoint Therapeutics stock. The stock was sold at an average price of $4.79, for a total transaction of $15,107.66.
On Tuesday, January 10th, William Garrett Gray sold 1,858 shares of Checkpoint Therapeutics stock. The stock was sold at an average price of $6.75, for a total transaction of $12,541.50.

Checkpoint Therapeutics Stock Performance

Shares of Checkpoint Therapeutics stock opened at $5.20 on Monday. Checkpoint Therapeutics, Inc. has a 52-week low of $3.56 and a 52-week high of $19.50. The stock has a market capitalization of $48.36 million, a price-to-earnings ratio of -0.60 and a beta of 1.52. The company has a fifty day moving average of $5.43 and a 200-day moving average of $2.86.

Wall Street Analyst Weigh In

CKPT has been the topic of a number of research analyst reports. Lake Street Capital decreased their price target on shares of Checkpoint Therapeutics from $41.00 to $32.00 in a report on Thursday. HC Wainwright reissued a “buy” rating and issued a $76.00 price target on shares of Checkpoint Therapeutics in a report on Thursday. Finally, B. Riley increased their price target on shares of Checkpoint Therapeutics from $7.00 to $15.00 and gave the stock a “buy” rating in a report on Monday, December 19th.

Institutional Investors Weigh In On Checkpoint Therapeutics

A number of institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. boosted its stake in shares of Checkpoint Therapeutics by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 3,017,783 shares of the company’s stock valued at $5,342,000 after purchasing an additional 41,489 shares in the last quarter. Morgan Jess S & Co. Inc. boosted its stake in shares of Checkpoint Therapeutics by 66.6% in the 3rd quarter. Morgan Jess S & Co. Inc. now owns 1,894,694 shares of the company’s stock valued at $1,970,000 after purchasing an additional 757,372 shares in the last quarter. Renaissance Technologies LLC boosted its stake in shares of Checkpoint Therapeutics by 307.5% in the 1st quarter. Renaissance Technologies LLC now owns 923,035 shares of the company’s stock valued at $1,634,000 after purchasing an additional 696,535 shares in the last quarter. Armistice Capital LLC purchased a new stake in Checkpoint Therapeutics during the 4th quarter valued at $3,536,000. Finally, Spotlight Asset Group Inc. purchased a new stake in Checkpoint Therapeutics during the 3rd quarter valued at $622,000.

Checkpoint Therapeutics Company Profile

(Get Rating)

Checkpoint Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. Its product portfolio includes CK-301, CK-101, CK-103, CK-302, and Anti-CAIX. The company was founded on November 10, 2014 and is headquartered in Waltham, MA.